Frank Xing, Xiaoxi Xu, Chunlan Dong, Wubin Qian, Huajun Yang, Zhengzheng Bao, Songling Zhang, Meng Qiao, Sheng Guo, and Qian Shi
CrownBio has developed a syngeneic model screening platform to facilitate the preclinical efficacy testing of immuno-oncology agents in vivo (MuScreen™, Poster 1665).
To combine the separate therapeutic strategies of activating immune cells against a tumor, and targeting the unique genetic characteristics of a cancer model, syngeneic mutation, expression, and drug response profiles need to be characterized.
This can provide a preclinical platform for the in vitro assessment of the combinatory effects of targeting both the immune system and specific oncogenic targets.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-02-19
2021-10-29
landing_page
PDX/Databases